沙库巴曲缬沙坦治疗心力衰竭的新进展

被引：111

作者：

刘滔 ^{[1
]}

徐俊波 ^{[1
,2
]}

吴镜 ^{[2
]}

机构：

[1] 遵义医学院

[2] 成都市第三人民医院心内科

来源：

心血管病学进展 | 2018年 / 39卷 / 03期

关键词：

心力衰竭; 药物治疗; 沙库巴曲缬沙坦; 血管紧张素受体-脑啡肽酶抑制剂;

D O I：

10.16806/j.cnki.issn.1004-3934.2018.03.046

中图分类号：

R541.6 [血液循环衰竭];

学科分类号：

100201 [内科学];

摘要：

心力衰竭是一种严重的心脏进展性疾病,其发病率、死亡率均较高。肾素-血管紧张素-醛固酮系统的过度激活在心力衰竭的病理生理学进展中起着重要作用。新型心力衰竭治疗药物沙库巴曲缬沙坦是首个血管紧张素受体-脑啡肽酶抑制剂,具有双重作用机制,在抑制脑啡肽酶的同时拮抗血管紧张素Ⅱ受体,已受到了欧美最新心力衰竭治疗指南的推荐。现对沙库巴曲缬沙坦的作用机制、临床研究、安全性及耐受性做一综述。

引用

页码：483 / 486

页数：4

共 9 条

[1]

《中国心血管病报告2016》概要 [J].

陈伟伟 ;

高润霖 ;

刘力生 ;

朱曼璐 ;

王文 ;

王拥军 ;

吴兆苏 ;

李惠君 ;

顾东风 ;

杨跃进 ;

郑哲 ;

蒋立新 ;

胡盛寿 .

中国循环杂志, 2017, 32 (06) :521-530

[2]

Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney [J].

Polhemus, David J. ;

Trivedi, Rishi K. ;

Gao, Juan ;

Li, Zhen ;

Scarborough, Amy L. ;

Goodchild, Traci T. ;

Varner, Kurt J. ;

Xia, Huijing ;

Smart, Frank W. ;

Kapusta, Daniel R. ;

Lefer, David J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (17) :2139-2153

[3]

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.[J].Ulrik M. Mogensen;Lars Køber;Søren L. Kristensen;Pardeep S. Jhund;Jianjian Gong;Martin P. Lefkowitz;Adel R. Rizkala;Jean L. Rouleau;Victor C. Shi;Karl Swedberg;Michael R. Zile;Scott D. Solomon;Milton Packer;John J.V. McMurray.American Heart Journal.2017,

[4]

Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens [J].

Senni, Michele ;

McMurray, John J. V. ;

Wachter, Rolf ;

McIntyre, Hugh F. ;

Reyes, Antonio ;

Majercak, Ivan ;

Andreka, Peter ;

Shehova-Yankova, Nina ;

Anand, Inder ;

Yilmaz, Mehmet B. ;

Gogia, Harinder ;

Martinez-Selles, Manuel ;

Fischer, Steffen ;

Zilahi, Zsolt ;

Cosmi, Franco ;

Gelev, Valeri ;

Galve, Enrique ;

Gomez-Doblas, Juanjo J. ;

Nociar, Jan ;

Radomska, Maria ;

Sokolova, Beata ;

Volterrani, Maurizio ;

Sarkar, Arnab ;

Reimund, Bernard ;

Chen, Fabian ;

Charney, Alan .

EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (09) :1193-1202

[5]

Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure [J].

McKie P.M. ;

Burnett J.C. ;

Jr. .

Current Heart Failure Reports, 2015, 12 (1) :7-14

[6]

PARADIGM-HF — The Experts' Discussion.[J].Mariell Jessup;Keith A.A. Fox;Michel Komajda;John J.V. McMurray;Milton Packer.The New England Journal of Medicine.2014, 11

[7]

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial [J].

Jhund, Pardeep S. ;

Claggett, Brian ;

Packer, Milton ;

Zile, Michael R. ;

Voors, Adriaan A. ;

Pieske, Burkert ;

Lefkowitz, Martin ;

Shi, Victor ;

Bransford, Toni ;

McMurray, John J. V. ;

Solomon, Scott D. .

EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (06) :671-677

[8]

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial [J].

Solomon, Scott D. ;

Zile, Michael ;

Pieske, Burkert ;

Voors, Adriaan A. ;

Shah, Amil ;

Kraigher-Krainer, Elisabeth ;

Shi, Victor ;

Bransford, Toni ;

Takeuchi, Madoka ;

Gong, Jianjian ;

Lefkowitz, Martin ;

Packer, Milton ;

McMurray, John J. V. .

LANCET, 2012, 380 (9851) :1387-1395

[9]

Heart failure and left ventricular remodelling in HFrEF and HFpEF..Lüscher TF;.Eur Heart J.2016,

← 1 →